The Influence of Nicotinamide on Health and Disease in the Central Nervous System
暂无分享,去创建一个
[1] J. Auwerx,et al. Modulating NAD+ metabolism, from bench to bedside , 2017, The EMBO journal.
[2] M. Pickard,et al. Nicotinamide alone accelerates the conversion of mouse embryonic stem cells into mature neuronal populations , 2017, PloS one.
[3] R. Zhai,et al. NMNAT: It's an NAD+ synthase… It's a chaperone… It's a neuroprotector. , 2017, Current opinion in genetics & development.
[4] Timothy A. Blenkinsop,et al. Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. , 2017, Cell stem cell.
[5] Zachary B. Loris,et al. The neuroprotective compound P7C3-A20 promotes neurogenesis and improves cognitive function after ischemic stroke , 2017, Experimental Neurology.
[6] Michael J. Phelan. Phase II Clinical Trial of Nicotinamide for the Treatment of Mild to Moderate Alzheimer's Disease , 2017 .
[7] Robert A. Smith,et al. Quinolinic acid induces neuritogenesis in SH‐SY5Y neuroblastoma cells independently of NMDA receptor activation , 2017, The European journal of neuroscience.
[8] M. Z. Cader,et al. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms , 2017, Trends in Neurosciences.
[9] Pete A. Williams,et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice , 2017, Science.
[10] K. P. Kepp,et al. Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.
[11] M. Hayden,et al. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington’s Disease Models , 2017, Molecular Neurobiology.
[12] S. Ito,et al. Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia , 2016, Proceedings of the National Academy of Sciences.
[13] Mark S. Schmidt,et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans , 2016, Nature Communications.
[14] J. Reid,et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. , 2016, Cell metabolism.
[15] D. Bennett,et al. NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies , 2016, PLoS biology.
[16] J. Milbrandt,et al. Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism , 2016, Neuron.
[17] E. Verdin. NAD+ in aging, metabolism, and neurodegeneration , 2015, Science.
[18] Aimin Liu,et al. What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics? , 2015, Expert review of neurotherapeutics.
[19] J. Morgan,et al. Low-dose niacin supplementation modulates GPR109A, niacin index and ameliorates Parkinson’s disease symptoms without side effects , 2015, Clinical case reports.
[20] James W. MacDonald,et al. A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury. , 2015, Journal of neurotrauma.
[21] N. Narayanan,et al. Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease , 2015, npj Parkinson's Disease.
[22] J. Milbrandt,et al. SARM1 activation triggers axon degeneration locally via NAD+ destruction , 2015, Science.
[23] Anil Kumar,et al. A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.
[24] F. Giorgini,et al. The kynurenine pathway and neurodegenerative disease. , 2015, Seminars in cell & developmental biology.
[25] Aaron Long,et al. Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model , 2015, BMC Neurology.
[26] Kamil Ugurbil,et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences , 2015, Proceedings of the National Academy of Sciences.
[27] J. Cannon,et al. Dietary Factors in the Etiology of Parkinson's Disease , 2015, BioMed research international.
[28] R. Ribchester,et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration , 2014, Cell Death and Differentiation.
[29] J. Morgan,et al. Upregulation of GPR109A in Parkinson’s Disease , 2014, PloS one.
[30] E. Koylu,et al. Ex vivo protective effects of nicotinamide and 3‐aminobenzamide on rat synaptosomes treated with Aβ(1–42) , 2014, Cell biochemistry and function.
[31] S. McKnight,et al. P7C3 Neuroprotective Chemicals Function by Activating the Rate-Limiting Enzyme in NAD Salvage , 2014, Cell.
[32] J. Gilley,et al. Wallerian degeneration: an emerging axon death pathway linking injury and disease , 2014 .
[33] Jose A. Santiago,et al. The emerging role of nutrition in Parkinson's disease , 2014, Front. Aging Neurosci..
[34] Qingtao Wang,et al. Overexpression of CD38 decreases cellular NAD levels and alters the expression of proteins involved in energy metabolism and antioxidant defense. , 2014, Journal of proteome research.
[35] D. Turner,et al. Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia , 2014, Neurobiology of Disease.
[36] E. Koylu,et al. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aβ(1–42)-induced rat model of Alzheimer's disease , 2014, Free radical research.
[37] Abbas Ali Mahdi,et al. Therapeutics of Alzheimer's disease: Past, present and future , 2014, Neuropharmacology.
[38] A. Keshavarzian,et al. Nutrition and Gastrointestinal Health as Modulators of Parkinson’s Disease , 2014 .
[39] R. Diem,et al. Dysfunction of neuronal calcium signalling in neuroinflammation and neurodegeneration , 2013, Cell and Tissue Research.
[40] P. Sachdev,et al. Mapping NAD+ metabolism in the brain of ageing Wistar rats: potential targets for influencing brain senescence , 2014, Biogerontology.
[41] E. Mercken,et al. Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging , 2013, Cell.
[42] M. Pickard,et al. Nicotinamide promotes neuronal differentiation of mouse embryonic stem cells in vitro , 2013, Neuroreport.
[43] A. Sauve,et al. Nicotinamide riboside, a trace nutrient in foods, is a Vitamin B3 with effects on energy metabolism and neuroprotection , 2013, Current opinion in clinical nutrition and metabolic care.
[44] G. Pasinetti,et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models , 2013, Neurobiology of Aging.
[45] M. Mattson,et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession , 2013, Neurobiology of Aging.
[46] J. López-Miranda,et al. Endothelial Aging Associated with Oxidative Stress Can Be Modulated by a Healthy Mediterranean Diet , 2013, International journal of molecular sciences.
[47] J. Milbrandt,et al. Protection of mouse retinal ganglion cell axons and soma from glaucomatous and ischemic injury by cytoplasmic overexpression of Nmnat1. , 2013, Investigative ophthalmology & visual science.
[48] K. Shibata,et al. Nutritional Aspect of Tryptophan Metabolism , 2013, International journal of tryptophan research : IJTR.
[49] K. Kraemer,et al. Introduction: The Diverse and Essential Biological Functions of Vitamins , 2012, Annals of Nutrition and Metabolism.
[50] S. McKnight,et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis , 2012, Proceedings of the National Academy of Sciences.
[51] R. Semba. The discovery of the vitamins. , 2012, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.
[52] G. Donmez. The neurobiology of sirtuins and their role in neurodegeneration. , 2012, Trends in pharmacological sciences.
[53] N. Braidy,et al. Age-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue , 2012, PloS one.
[54] Adrian C. Williams,et al. Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra , 2012, Current gerontology and geriatrics research.
[55] Efsa Panel on Dietetic Products. Scientific Opinion on Dietary Reference Values for iodine. , 2014 .
[56] R. Zhai,et al. CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. , 2012, Human molecular genetics.
[57] B. Barres,et al. Axon degeneration: Molecular mechanisms of a self-destruction pathway , 2012, The Journal of cell biology.
[58] J. Toldi,et al. Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach , 2011, Journal of the Neurological Sciences.
[59] C. V. Haar,et al. Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury , 2011, Behavioural Brain Research.
[60] A. Blokland,et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid , 2011, Neurobiology of Aging.
[61] P. Kusumanchi,et al. NMNAT expression and its relation to NAD metabolism. , 2011, Current medicinal chemistry.
[62] A. Messer,et al. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease , 2011, Neurobiology of Disease.
[63] Jing Wang,et al. Inhibition of Sirt1 promotes neural progenitors toward motoneuron differentiation from human embryonic stem cells. , 2011, Biochemical and biophysical research communications.
[64] Jing Wang,et al. Inhibition of Sirt 1 promotes neural progenitors toward motoneuron differentiation from human embryonic stem cells , 2011 .
[65] M. Chopp,et al. Niacin, an Old Drug, has New Effects on Central Nervous System Disease , 2010 .
[66] G. Torres,et al. Distribution Analysis of Deacetylase SIRT1 in Rodent and Human Nervous Systems , 2010, Anatomical record.
[67] Adriana B Ferreira,et al. Increased Membrane Cholesterol Might Render Mature Hippocampal Neurons More Susceptible to β-Amyloid-Induced Calpain Activation and Tau Toxicity , 2009, The Journal of Neuroscience.
[68] D. Dougherty,et al. L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications , 2009, International journal of tryptophan research : IJTR.
[69] N. Braidy,et al. Promotion of cellular NAD+ anabolism: Therapeutic potential for oxidative stress in ageing and alzheimer’s disease , 2008, Neurotoxicity Research.
[70] S. Imai. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. , 2009, Current pharmaceutical design.
[71] E. Chini. CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. , 2009, Current pharmaceutical design.
[72] F. LaFerla,et al. Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-Phosphotau , 2008, The Journal of Neuroscience.
[73] J. Schneider,et al. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP‐induced parkinsonism , 2008, The European journal of neuroscience.
[74] J. Kirkland,et al. The role of dietary niacin intake and the adenosine-5′-diphosphate-ribosyl cyclase enzyme CD38 in spatial learning ability: is cyclic adenosine diphosphate ribose the link between diet and behaviour? , 2008, Nutrition Research Reviews.
[75] F. Zipp,et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors , 2008, Nature Cell Biology.
[76] R. de Cabo,et al. Mechanisms Underlying Caloric Restriction and Lifespan Regulation: Implications for Vascular Aging , 2008, Circulation research.
[77] M. Seman,et al. Extracellular NAD and ATP: Partners in immune cell modulation , 2007, Purinergic Signalling.
[78] C. Mathers,et al. Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.
[79] Julie A Schneider,et al. Thoughts on B-vitamins and dementia. , 2006, Journal of Alzheimer's disease : JAD.
[80] Adrian C. Williams,et al. Nicotinamide: a double edged sword. , 2005, Parkinsonism & related disorders.
[81] J. Alisky. Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash—A case report , 2005, Nutritional neuroscience.
[82] R. Tuma. NAD to the rescue , 2005, The Journal of Cell Biology.
[83] A. Williams,et al. Parkinson's disease: the first common neurological disease due to auto-intoxication? , 2005, QJM : monthly journal of the Association of Physicians.
[84] Adrian C. Williams,et al. Autotoxicity, methylation and a road to the prevention of Parkinson’s disease , 2005, Journal of Clinical Neuroscience.
[85] A. Williams,et al. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases. , 2005, Medical hypotheses.
[86] J. Milbrandt,et al. Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration , 2004, Science.
[87] D. Bennett,et al. Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[88] J. Simon,et al. Neuroscience. NAD to the rescue. , 2004, Science.
[89] V. Demarin,et al. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. , 2004, Drugs under experimental and clinical research.
[90] R. Spector. Niacinamide transport through the blood-brain barrier , 2004, Neurochemical Research.
[91] R. Waring,et al. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease , 2003, Neuroscience Letters.
[92] K. Maiese,et al. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. , 2003, Trends in pharmacological sciences.
[93] Bin Liu,et al. Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.
[94] R. Waring,et al. Expression of Nicotinamide N‐Methyltransferase (E.C. 2.1.1.1) in the Parkinsonian Brain , 2002, Journal of neuropathology and experimental neurology.
[95] S. Yamaguchi,et al. Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease , 2001, Neuroscience Letters.
[96] K. Maiese,et al. Nicotinamide: A Nutritional Supplement that Provides Protection Against Neuronal and Vascular Injury. , 2001, Journal of medicinal food.
[97] P. Bingley,et al. Safety of high-dose nicotinamide: a review , 2000, Diabetologia.
[98] B. Everitt,et al. Age-dependence of malonate-induced striatal toxicity , 2000, Experimental Brain Research.
[99] C. Ogilvy,et al. Delayed treatment with nicotinamide (Vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. , 2000, Stroke.
[100] K. Jellinger,et al. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia , 2000, Journal of Neural Transmission.
[101] D. Guastella,et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[102] O. Axelson,et al. Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.
[103] N. Nishiyama,et al. 3‐Hydroxykynurenine, an Endogenous Oxidative Stress Generator, Causes Neuronal Cell Death with Apoptotic Features and Region Selectivity , 1998, Journal of neurochemistry.
[104] A. Galione,et al. Nicotinamide inhibits cyclic ADP-ribose-mediated calcium signalling in sea urchin eggs. , 1996, The Biochemical journal.
[105] G. Ulm,et al. Diet and Parkinson's disease II , 1996, Neurology.
[106] J. Birkmayer. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. , 1996, Annals of clinical and laboratory science.
[107] B. Rosen,et al. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate , 1994, Annals of neurology.
[108] P. Debré,et al. The lymphocyte surface antigen CD38 acts as a nicotinamide adenine dinucleotide glycohydrolase in human T lymphocytes , 1993, European journal of immunology.
[109] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[110] B. Hyman,et al. Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate , 1993, Journal of neurochemistry.
[111] H. Herzog,et al. Effect of Huntington's and Alzheimer's diseases on the transport of nicotinic acid or nicotinamide across the human blood-brain barrier. , 1991, Advances in experimental medicine and biology.
[112] Y. Kagawa,et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.
[113] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[114] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[115] R. Levine,et al. Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. , 1979, Science.